Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma

NCT04401813 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
97
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.